Two mid‑stage readouts shifted expectations in atopic dermatitis. Evommune reported EVO301 achieved a statistically significant placebo‑adjusted improvement in EASI scores at Week 12 that the company and analysts say is competitive with marketed agents; the result sent shares sharply higher. Separately, Nektar disclosed that rezpegaldesleukin (rezpeg) maintained and in some cases deepened skin‑clearance responses out to 52 weeks, with 71% (monthly) and 83% (quarterly) of responders maintaining EASI‑75 at 36 weeks in its follow‑up cohort. Companies are positioning the data as commercial and regimen‑differentiation drivers versus incumbent biologics such as Dupixent. Both programs now face confirmatory Phase III designs and competitive positioning debates over dosing frequency, durability, and safety.